A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms LAVOLTA I
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 08 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2017 Results (n=2149) of pooled post hoc analysis of LAVOLTA I and LAVOLTA II trials assessing association between seasonal variability and clinical response of lebrikizumab, published in the Journal of Allergy and Clinical Immunology
    • 30 Sep 2016 This trial was prematurely ended in Italy (end date: 24-06-2016), according to the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top